{
    "clinical_study": {
        "@rank": "75412", 
        "arm_group": [
            {
                "arm_group_label": "Pramlintide 6 mcg per unit of insulin dose", 
                "arm_group_type": "Experimental", 
                "description": "The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 6 mcg for each unit of insulin."
            }, 
            {
                "arm_group_label": "Pramlintide 9 mcg per unit of insulin dose", 
                "arm_group_type": "Experimental", 
                "description": "The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 9 mcg for each unit of insulin."
            }, 
            {
                "arm_group_label": "Pramlintide 12 mcg per unit of insulin dose", 
                "arm_group_type": "Experimental", 
                "description": "The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 12 mcg for each unit of insulin."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To examine the effects of different fixed pramlintide:insulin dose ratios in subjects with\n      type 1 diabetes on postprandial plasma glucose concentrations"
        }, 
        "brief_title": "Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 1 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Is 18 to 70 years old\n\n          -  Is male, or is female and meets all the following criteria:\n\n               1. Not breastfeeding\n\n               2. Negative pregnancy test result and, if of childbearing potential, must practice\n                  and be willing to continue to practice appropriate birth control\n\n          -  Has been diagnosed with type 1 diabetes mellitus for at least 1 year and not\n             achieving glycemic goal while on MDI of insulin\n\n          -  Has HbA1c between 7.0% and 9.0%\n\n          -  Has been on MDI of regular insulin, at a dose not to exceed 10 units/breakfast for at\n             least 3 months or has been on continuous subcutaneous insulin infusion (CSII), at a\n             dose not to exceed 10 units/breakfast, for at least 3 months and is willing to switch\n             to an MDI insulin regimen for 1 day prior to enrollment and through the study\n\n          -  Has a body mass index (BMI) <30 kg/m2\n\n        Exclusion Criteria:\n\n          -  Has experienced recurrent severe hypoglycemia requiring assistance within 6 months\n             before Visit 1 Screening\n\n          -  Has a history of hypoglycemia unawareness\n\n          -  Has a confirmed diagnosis of gastroparesis\n\n          -  Has been treated, is currently being treated, or is expected to require or undergo\n             treatment with the following medications:\n\n               1. Any antihyperglycemic agent other than insulin\n\n               2. Drugs that directly affect gastrointestinal motility (e.g., anticholinergic\n                  agents such as atropine)\n\n               3. Drugs that slow the intestinal absorption of nutrients (e.g., \u03b1-glucosidase\n                  inhibitors.\n\n          -  Has a clinically significant medical condition that could potentially affect study\n             participation and/or personal well-being, as judged by the investigator, including\n             but not limited to the following conditions:\n\n               1. Hepatic disease\n\n               2. Renal disease\n\n               3. Gastrointestinal disease\n\n               4. Pulmonary disease\n\n               5. Organ transplantation\n\n               6. Chronic infection (e.g., tuberculosis, human immunodeficiency virus, hepatitis B\n                  virus, or hepatitis C virus)\n\n          -  Is currently treated or has been previously treated with SYMLIN/pramlintide or has\n             participated in a SYMLIN/pramlintide clinical study within 3 months of Visit 1\n             (Screening).\n\n          -  Has any clinically significant laboratory findings or medical history that may affect\n             successful completion of the study and/or personal well-being\n\n          -  Has donated blood within 2 months or is planning to donate blood during the study.\n\n          -  Has had a major surgery or a blood transfusion within 2 months\n\n          -  Has received any investigational drug within 1 month\n\n          -  Has known allergies or hypersensitivity to any component of study treatment.\n\n          -  Is an immediate family member of personnel directly affiliated with the study at the\n             clinical study site, or is directly affiliated with the study at the clinical study\n             site.\n\n          -  Is employed by Amylin Pharmaceuticals, Inc (Amylin) (that is an employee, temporary\n             contract worker, or designee responsible for the conduct of the study)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01708044", 
            "org_study_id": "ABA163"
        }, 
        "intervention": {
            "arm_group_label": [
                "Pramlintide 6 mcg per unit of insulin dose", 
                "Pramlintide 9 mcg per unit of insulin dose", 
                "Pramlintide 12 mcg per unit of insulin dose"
            ], 
            "intervention_name": "Pramlintide acetate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Pramlintide", 
                "Insulin", 
                "Islet Amyloid Polypeptide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Pramlintide,", 
            "insulin,", 
            "type 1 diabetes,", 
            "reduction in postprandial glucose,", 
            "pramlintide:insulin dose-ratio"
        ], 
        "lastchanged_date": "February 26, 2013", 
        "location": {
            "contact": {
                "last_name": "Amylin Call Center", 
                "phone": "800-349-8919"
            }, 
            "facility": {
                "address": {
                    "city": "Portland", 
                    "country": "United States", 
                    "state": "Oregon"
                }, 
                "name": "Research Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Randomized, Placebo-Controlled Single-Blind, Dose-Ranging, 4-Way Crossover Study to Evaluate the Effect of Different Fixed Pramlintide: Insulin Dose Ratios on Postprandial Glycemic Control in Subjects With Type 1 Diabetes Mellitus", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incremental area under the concentration-time curve (AUC(0-3 h)) of plasma glucose concentrations for each treatment", 
            "safety_issue": "No", 
            "time_frame": "AUC 0-3 hrs compared to Placebo"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01708044"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incremental AUC (0-3 h) of plasma glucagon", 
                "safety_issue": "No", 
                "time_frame": "0-3 hrs compared to Placebo"
            }, 
            {
                "measure": "Absolute AUC (0-3 h), peak plasma concentration (Cmax), Cave, and Tmax of glucagon of plasma glucose.", 
                "safety_issue": "No", 
                "time_frame": "0-3 hrs compared to Placebo"
            }, 
            {
                "measure": "PK of pramlintide", 
                "safety_issue": "No", 
                "time_frame": "0-3 hrs compared to Placebo"
            }, 
            {
                "measure": "Safety", 
                "safety_issue": "No", 
                "time_frame": "0-3 hrs compared to Placebo"
            }
        ], 
        "source": "Amylin Pharmaceuticals, LLC.", 
        "sponsors": {
            "collaborator": {
                "agency": "Juvenile Diabetes Research Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Amylin Pharmaceuticals, LLC.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}